Video

Dr. Carey Discusses the CALGB40502 Trial in TNBC

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC).

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC).

In this trial, 799 patients were randomized to receive paclitaxel (n = 283), nab-paclitaxel (n = 271), or ixabepilone (n = 245), and most patients also received concurrent bevacizumab (Avastin; 98%). Nab-paclitaxel (Abraxane) was given at a higher-than-approved dose of 150 mg/m2 weekly. Paclitaxel was administered at 90 mg/m2 and ixabepilone was administered at 16 mg/m2 weekly.

This phase III trial showed improvements in overall survival (OS) and progression-free survival of nab-paclitaxel compared with standard paclitaxel for patients with metastatic TNBC. The median OS with nab-paclitaxel was 21.0 months compared with 15.3 months with standard paclitaxel, representing a 26% reduction in risk of death. The hazard ratio for the comparison was 0.74 (95% CI, 0.51-1.07).

Related Videos
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute